These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11923351)

  • 1. Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.
    Cho YK; Sung H; Ahn SH; Bae IG; Woo JH; Won YH; Kim DG; Kang MW
    J Clin Microbiol; 2002 Apr; 40(4):1319-25. PubMed ID: 11923351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors.
    Re MC; Bon I; Monari P; Borderi M; Gibellini D; Schiavone P; Vitone F; Chiodo F; La Placa M
    Int J Antimicrob Agents; 2003 Oct; 22(4):388-94. PubMed ID: 14522102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
    Parikh UM; Bacheler L; Koontz D; Mellors JW
    J Virol; 2006 May; 80(10):4971-7. PubMed ID: 16641288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
    Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically relevant genotype interpretation of resistance to didanosine.
    Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
    Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of genotypic resistance to nucleoside analogues, nonnucleoside analogues, and protease inhibitors in HIV-infected persons in Athens, Greece.
    Panos G; Charatsis G; Paparizos V; Kazantzi M; Falagas ME
    AIDS Res Hum Retroviruses; 2008 Jan; 24(1):43-51. PubMed ID: 18275347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
    Gottlieb GS; Badiane NM; Hawes SE; Fortes L; Toure M; Ndour CT; Starling AK; Traore F; Sall F; Wong KG; Cherne SL; Anderson DJ; Dye SA; Smith RA; Mullins JI; Kiviat NB; Sow PS;
    Clin Infect Dis; 2009 Feb; 48(4):476-83. PubMed ID: 19143530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.
    Sarmati L; Nicastri E; Parisi SG; d'Ettorre G; Mancino G; Narciso P; Vullo V; Andreoni M
    J Clin Microbiol; 2002 Feb; 40(2):335-40. PubMed ID: 11825939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors.
    Montes B; Segondy M
    J Med Virol; 2002 Mar; 66(3):299-303. PubMed ID: 11793380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.